Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 2 (2005), Issue 11 (November)

1. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
   J Natl Cancer Inst, 97(21): 1611-5. [Abstract] [Full-text]
2. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
   Breast Cancer Res Treat. [Abstract] [Full-text]
3. Can we approach zero relapse in breast cancer?
   Oncologist, 10: 9-17. [Abstract] [Full-text]
4. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
   Cancer, 104(10): 2149-55. [Abstract] [Full-text]
5. Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer.
   Mol Cell Proteomics, 4(11): 1686-96. [Abstract] [Full-text]
6. Prognostic and predictive factors revisited.
   Breast, 14(6): 493-9. [Abstract] [Full-text]
7. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
   Breast J, 11(6): 433-9. [Abstract] [Full-text]
8. Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
   Tumour Biol, 26(6): 281-93. [Abstract] [Full-text]
9. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma.
   Ann Oncol, 16(12): 1889-97. [Abstract] [Full-text]
10. Trastuzumab: updates and future issues.
    Cancer Chemother Pharmacol, 56: 94-9. [Abstract] [Full-text]
11. Resistance to endocrine therapy in breast cancer.
    Cancer Chemother Pharmacol, 56: 39-46. [Abstract] [Full-text]
12. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
    J Cancer Res Clin Oncol, 132(1): 9-18. [Abstract] [Full-text]
13. Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.
    Hum Pathol, 36(12): 1273-80. [Abstract] [Full-text]
14. Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin.
    Oncologist, 10(10): 780-91. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.